Goldman Sachs invests in price and investment costs for Ideaya Biosciences from Investing.com

The service helped Goldman Sachs in the Kaufempfehlung for Aktien of Ideaya Biosciences (NASDAQ:IDYA) with a US share price of US$48.00. The positive influence of the investment bank is evident from research of clinical data on Darovasertib (Daro), a Protein Kinase C Inhibitor (PKC), which allows the treatment to improve the stages of arterial melanoma (UM), a seltenen Form von Augenkrebs.

Ideaya Biosciences has conducted a Phase 2/3 clinical trial of Darovasertib in combination with Pfizer’s MET inhibitor Crizotinib (Crizo) in patients with HLA-A2 negative UM metastasis. This study can carry out the positive phase 2 recognition of a road for a revetment and full-fledged Zulassung study.

In parallel with a phase 2 study, the potential of darovasertib as monotherapy in neoadjuvant treatment was evaluated. See here the erhalt of the auges and the reduction of the beam dose. If the combination with crizotinib is used for the unresolved relief, the focus will be on the rezidiv-free unrestrained (RFS) basis.

The Goldman Sachs analyst said that in such a study, Darovasertib also has another sponsored study investigating a possible anti-tumor activation in neoadjuvant UM research. There are many more data updates that will follow this long term and the path for a separate phase 3 trial in the new complementary treatment.

Please note that the positive results from Goldman Sachs are a Umsatzprognosis for Darovasertib nach corrected. The analysts have now started, while the US$3.0 billion was estimated to be a German scaffolding that would generate the previous forecast of US$2.6 billion. This passage reflects the drug’s market potential and Ideaya Biosciences’ strategic positioning in the UM treatment space more broadly.

In others, active research has developed IDEAYA Biosciences in the medical field. Cost-effective results from the EORTC-NCI-AACR-Symposium Ergebnisse der Phase-1-Erweiterungsstudie seines Wirkstoffkansen IDE397. This MAT2A inhibitor is used in patients with MTAP deletion urothelkarzine and niece-small lung cancer.

This message comes from part of the research that has been turned into the Phase-2-Studien of Leitwirkstoffs Darovasertib. Other notable results included significant tumor shrinkage and the occurrence of auges in patients with neoadjuvant venous melanoma. These results led IDEAYA Biosciences to conduct a Phase 3 trial of a plan.

More financial institutions have made a positive contribution to the financing of the company. Mizuho Securities and RBC Capital hold an “Outperform” rating party at US$55. 61 US dollars. Auch Citi validates your purchase with an unaltered rate of 58 US dollars. The development of IDEAYA Biosciences has come to an end.

InvestingPro Acknowledgment

Während Goldman Sachs has a reasonable chance for Ideaya Biosciences (NASDAQ: IDYA) with a price of 48 US dollars is a ratsam, as is financial knowledge and expertise of experts. Laut InvestingPro-Daten believes the market capitalization of IDYA at 2.57 billion US dollars, was the investor in the potential of the broader mirror of the economy. The active financing of internal economies presents a different picture.

InvestingPro-Tipps I said that IDYA had more money as debt in the blessing Bilanz hält, was financial flexibility at the Weiterentwicklung seiner clinical trials that were possible. This is one of the main consequences of the capital-intensive nature of the medicinal lung. Once the liquid assets of the internal economies were eliminated, solid financial financing was left behind.

InvestingPro tips were given on the previous page, while the analysts have developed an investment strategy for the successful years and the external companies have not been profitable in those years. The target of the typical profile is a biotech industry in the development phase, while the significant features often hint at further development.

It is a fact that IDYA’s Action has been a strong performer in recent years, reflecting the long-awaited investor optimism of the blessing pipeline more broadly. All the action does is an underachievement and it’s worth doing.

For investors making such an analysis, InvestingPro offers 11 other tips for IDYA, one of the financial benefits and market position of their external economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.